What Dr. Fowler's IV Vitamin C Research Reported, in Plain Words
Every so often we come across a research talk that's worth passing along simply because it shows how careful scientists work through a question. This week's recap is from a talk given at the Fralin Biomedical Research Institute by Dr. Alpha Barry Fowler III, a researcher who has spent years studying high-dose intravenous vitamin C in very sick hospital patients. Here is a short summary of what he reported, in plain words.
Where the question started
Dr. Fowler describes an observation from the intensive care unit: patients with sepsis, a severe body-wide response to infection, often have very low levels of vitamin C in their blood. That observation led his team and others to ask whether giving high doses of vitamin C through an IV, in a hospital setting, might be worth studying in a formal way.
The safety trial
He reviews an early safety trial at Virginia Commonwealth University (VCU). Patients received either a placebo or intravenous vitamin C at one of two doses, 50 or 200 milligrams per kilogram of body weight per day. The main purpose of a trial like this is to look at safety and tolerability so researchers know whether larger studies can go forward. Early trials are small, and they are designed to answer narrow questions.
CITRIS-ALI
Dr. Fowler then discusses a larger trial called CITRIS-ALI. In that study, high-dose IV vitamin C was started after patients already had established lung injury. The trial's main measure, a change in the SOFA score that doctors use to track organ function, did not differ between the vitamin C group and the placebo group. In other words, the primary result was not a win.
He also describes some secondary measures, such as time to leaving the ICU and survival curves, that drew attention from researchers. Secondary results like these are not the main question a trial was built to answer, so researchers regard them as ideas for further study rather than conclusions. Dr. Fowler notes that questions about starting earlier, or giving it for longer, are still being studied.
Why we're sharing this
We like this talk because it's honest about the results, including the one that didn't come out the way researchers hoped. That's how good science works: a question, a careful trial, a clear answer to the main question, and new questions for the next study. Hospital research on very sick patients is a very different setting from everyday life, and this summary shouldn't be read as saying anything about other uses.
Everything in this post is Dr. Fowler's research framing, reported as he presented it. It is education only, not medical advice, and it doesn't replace a conversation with your own doctor.
Credit
Inspiration only: Fralin Biomedical Research Institute / Dr. Alpha Barry Fowler III, "Intravenous Vitamin C: Pathway to a New Therapy to Save Lives," https://www.youtube.com/watch?v=HXs5Xzr6qCI. No footage from the talk was used. Our short recap uses our own still images and music.
Stanford Clinic & Herb Shop · Lucedale, MS
Comments